Cardiovascular consequences of poor compliance to antihypertensive therapy

被引:18
作者
Grassi, Guido [1 ,2 ]
Seravalle, Gino [2 ]
Mancia, Giuseppe [1 ,2 ]
机构
[1] Univ Milano Bicocca, Osped San Gerardo, Dipartimento Med Clin Prevenz & Biotecnol Sanit, Milan, Italy
[2] Ist Auxol Italiano, Milan, Italy
关键词
Adherence; angiotensin II receptor blockers; antihypertensive treatment; clinical trials; compliance to treatment; CV disease; CHRONIC HEART-FAILURE; BLOOD-PRESSURE CONTROL; END-POINT REDUCTION; DIAGNOSED HYPERTENSIVE PATIENTS; ANGIOTENSIN-RECEPTOR BLOCKADE; VENTRICULAR SYSTOLIC FUNCTION; CONVERTING-ENZYME INHIBITORS; INITIAL-DRUG CHOICE; LOSARTAN INTERVENTION; HIGH-RISK;
D O I
10.3109/08037051.2011.557902
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Despite the proven efficacy of current strategies for cardiovascular (CV) risk reduction, a considerable gap remains between the risk reductions achieved in clinical trials and those seen in clinical practice. A major reason for this is poor compliance to medication, which has been extensively documented for antihypertensive therapy. Low adherence results in suboptimal blood pressure control, which is associated with adverse CV outcomes and increased treatment costs. Adverse effects of medication are an important cause of diminished adherence. Angiotensin II receptor blockers (ARBs) may offer better long-term tolerability than other classes of antihypertensive agent, and this is likely to be a major factor in the high levels of adherence and persistence seen with these agents. This could have implications for CV protection, as confirmed by the results of recent clinical trials. Thus, ARBs should be considered as an alternative to angiotensin-converting enzyme inhibitors in patients at risk of low adherence.
引用
收藏
页码:196 / 203
页数:8
相关论文
共 50 条
  • [31] Factors influencing antihypertensive medication compliance in Taiwan: a nationwide population-based study
    Lee, Chien-Ying
    Huang, Chun-Che
    Shih, Hung-Che
    Huang, Kuang-Hua
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2013, 20 (06) : 930 - 937
  • [32] Determining the difference in medication compliance between the general patient population and patients receiving antihypertensive therapy: A case study
    Culig, Josip
    Leppee, Marcel
    Boskovic, Jelena
    Eric, Mirela
    ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (07) : 1143 - 1152
  • [33] A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients
    Garcia-Donaire, J. A.
    Segura, J.
    Cerezo, C.
    Ruilope, L. M.
    BLOOD PRESSURE, 2011, 20 (06) : 322 - 334
  • [34] Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure
    Asayama, Kei
    Ohkubo, Takayoshi
    Metoki, Hirohito
    Obara, Taku
    Inoue, Ryusuke
    Kikuya, Masahiro
    Thijs, Lutgarde
    Staessen, Jan A.
    Imai, Yutaka
    HYPERTENSION RESEARCH, 2012, 35 (11) : 1102 - 1110
  • [35] Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure
    Kei Asayama
    Takayoshi Ohkubo
    Hirohito Metoki
    Taku Obara
    Ryusuke Inoue
    Masahiro Kikuya
    Lutgarde Thijs
    Jan A Staessen
    Yutaka Imai
    Hypertension Research, 2012, 35 : 1102 - 1110
  • [36] Antihypertensive therapy and cerebrovascular protection
    Volpe, Massimo
    Tocci, Giuliano
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2006, 15 (05) : 498 - 504
  • [37] Compliance and persistence of free-combination antihypertensive therapy versus single-pill combination in Korean hypertensive patients
    Min, Jin-Young
    Min, Kyoung-Bok
    Hong, Ji-Min
    Kim, Eu-Gene
    Yang, Bong-Min
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (04) : 4576 - 4577
  • [38] Antihypertensive therapy and endothelial function
    Nadar, S
    Blann, AD
    Lip, GYH
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (29) : 3607 - 3614
  • [39] Antiretroviral Treatment and Antihypertensive Therapy
    Robles, Nicolas R.
    Fici, Francesco
    Valladares, Julian
    Grassi, Guido
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (40) : 4116 - 4124
  • [40] Renal protection by antihypertensive therapy
    Luis M. Ruilope
    Julian Segura
    Current Hypertension Reports, 2002, 4 : 324 - 328